Navigation Links
CT Imaging With Novel Contrast Agent May Predict Heart Attack in Waiting

A new imaging technology may hold the key to not only stopping heart attacks in their tracks but also preventing them for ever occurring//. Researchers at Mount Sinai School of Medicine have shown the use computed tomography (CT) imaging along with a novel contrast agent know as N1177 can detect dangerous, high-risk plaque which cause heart attack and stroke. The findings may help physicians diagnosis a heart attack before the attack occurs.

High-risk plaque is characterized by their cellular and biologic structure. High-risk plaque rich in macrophages or cells can rupture, eventually causing a heart attack or stroke. Early identification of high-risk plaque in coronary arteries may be useful to prevent cardiac events but one major hurdle in detecting high-risk plaque is the lack of an imaging modality that allows physicians to see the composition of dangerous plaque, explains study author Zahi A. Fayad, PhD, FAHA, FACC, Professor of Radiology and Medicine (Cardiology) and director of the Translational and Molecular Imaging Institute at Mount Sinai School of Medicine. “Coronary CT imaging has advanced the diagnosis and prognosis of heart disease,” says Dr. Fayad. “But, what if we had the opportunity to prevent a heart attack from happening? This modality may allow us to do just that.”

A team of researchers led by Dr. Fayad tested an iodinated nanoparticulate contrast agent called N1177 for the detection of macrophages in an animal model with 64-slice CT. High-risk plaque in this animal model contained high levels of macrophages which are similar in size and content to human coronary plaques. Researchers compared the enhancement of macrophage rich plaque after the injection of N1177 and a conventional CT contrast agent. The enhancement of the macrophage rich plaque after the injection of N1177 was significantly higher and specific inside of the vessel wall than after injecting the conventional CT contrast agent.

“We were amazed a t these results. The introduction of N1177 allows us for the first time to look directly at the coronary arteries and pinpoint these dangerous, heart attack causing plaque,” said Dr. Fayad.

“N1177 had successfully progressed through Phase 1 clinical trials for use as a cancer staging agent,” said Don Skerrett, chief executive officer of NanoScan Imaging, LLC, and provider of N1177. “The unique properties of N1177 make it a versatile agent with a range of applications including: intravenous administration for the assessment of atherosclerosis and identification of vulnerable plaque, inhalation delivery for improved lung cancer staging and subcutaneous delivery for assessing cancerous extension into lymph nodes.”

The Mount Sinai researchers also believe this development may have broader clinical implication.

“N1177-enhanced CT will be helpful for diagnosis and prognosis of disease states. In the future, this technology may allow for the targeting of macrophages to specifically dispense therapeutic agents to disease tissue.”

Source-Newsise
SRM
'"/>




Related medicine news :

1. Imaging Modality That Might Help Diagnose Depression
2. Being Obese Increases Ones Risk Of A wrong Diagnosis During Medical Imaging
3. Optical Imaging Added To Ultrasound To Improve Imaging Of Breast Cancer
4. Using Eyes As The Line Of Reference For Fetal Brain Imaging
5. Three In One Ultrasound Probe For 3-D Imaging Of Heart And Tissue Destruction Developed
6. New Computerized Imaging Systems Help In Better Dental Treatment Planning
7. Magnetic Resonance Imaging Can Now Be Used For Mind Reading
8. New Cardiac Angiography Technique For Improved Imaging Of Coronary Veins
9. Brain Is More Active While Hiding The Truth, Reveals fMRI Imaging
10. 3-D Imaging For Monitoring Reactor Systems, Power Plants
11. Brian Imaging Can Foretell Results Of Treating Depression
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 26, 2016 One of Australia,s ... the formation of a new biotechnology company, Noxopharm Limited [ABN 50 ... an IPO and to list on the ASX. Noxopharm ... ready to enter a Phase 1 clinical study later this year. ... address one of the biggest problems facing cancer patients - the ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: